Insellar raises €400K pre-seed for European psychiatric BCI — Germany first market
Summary
Berlin-based Insellar raised €400K in a pre-seed round in April 2026 to build a functional prototype and preclinical proof of concept for a BCI and neurostimulation device targeting treatment-resistant depression in Europe. The tiny pre-seed reflects European early-stage deep tech funding patterns but is strategically significant as it adds a German psychiatric BCI startup to the growing European ecosystem building on CorTec's and MintNeuro's work.
Why it matters
Insellar's €400K pre-seed is the European grassroots answer to Motif Neurotech's US FDA IDE approval. Germany's early access medical technology pathways, familiarity with BCI from CorTec, and large refractory depression patient population make it a logical European base for psychiatric BCI development. Early-stage European psychiatric BCI companies will benefit from Motif's US clinical data as regulatory precedent.
Want the full NeurotechMag Pro intelligence database?
Access 800+ papers, trials, patents, funding rounds and news items — updated daily.
Start free trial